You haven't searched anything yet.
This is what you will do:
The successful candidate will be a member of the Genomic Medicine Drug Product Development group within Injectable DPD. This individual will have a direct impact on a dynamic and growing group of scientists and engineers developing adeno-associated virus (AAV) based gene therapy products within the larger Alexion Rare Disease Business Unit organization.
This team member will implement studies for the development of AAV formulations, fill-finish processes, and clinical device compatibility to ensure clinical and commercial readiness.
You will be responsible for:
You will need to have:
Expectation of working in the office 4 days a week statement: When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working give us the platform we need to connect, work at pace and challenge perceptions. That’s why we work, on average, a minimum of four days per week from the office. But that doesn’t mean we’re not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.
AstraZeneca requires all US employees to be fully vaccinated for COVID-19 but will consider requests for reasonable accommodations as required by applicable law.
AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.
Other
Pharmaceutical
$130k-162k (estimate)
03/24/2024
07/03/2024
alexion.com
BOSTON, MA
3,000 - 7,500
1992
Public
LUDWIG N HANTSON
$5B - $10B
Pharmaceutical
Alexion develops and commercializes immunoregulatory drugs for the treatment of autoimmune and cardiovascular diseases.